National cancer institute of Canada clinical trials group MAP.3 trial:: Evaluation of exemestane to prevent breast cancer in postmenopausal women

被引：12
|
作者：
Goss, Paul E. [1 ]
Richardson, Harriet [2 ]
Chlebowski, Rowan [3 ]
Johnston, Dianne [2 ]
Sarto, Gloria E. [4 ]
Maunsell, Elizabeth [5 ]
Ingle, James N. [6 ]
Ales-Martinez, Jose E. [7 ]
机构：
[1] Harvard Univ, Sch Med, Boston, MA USA
[2] Queens Univ, Natl Canc Inst, Clin Trials Grp, Kingston, ON K7L 3N6, Canada
[3] Harbor UCLA Med Ctr, Los Angeles Biomed Res Inst, Torrance, CA 90509 USA
[4] Univ Wisconsin, Sch Med, Madison, WI 53706 USA
[5] Univ Laval, Fac Med, Unite Rech Sante Populat, Quebec City, PQ G1K 7P4, Canada
[6] Mayo Clin, Rochester, MN USA
[7] Hosp Ruber Internacl, Madrid, Spain
来源：
CLINICAL BREAST CANCER | 2007年 / 7卷 / 11期
关键词：
aromatase inhibitors; estrogen receptor; selective estrogen receptor modulators;
D O I：
10.3816/CBC.2007.n.057
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
[No abstract available]
引用
收藏
页码：895 / 900
页数：6
相关论文
共 50 条
  • [1] Baseline estrogen levels in postmenopausal women participating in the MAP.3 breast cancer chemoprevention trial
    Richardson, Harriet
    Ho, Vikki
    Pasquet, Romain
    Singh, Ravinder J.
    Goetz, Matthew P.
    Tu, Dongsheng
    Goss, Paul E.
    Ingle, James N.
    MENOPAUSE-THE JOURNAL OF THE NORTH AMERICAN MENOPAUSE SOCIETY, 2020, 27 (06): : 693 - 700
  • [2] Bone density and structure in healthy postmenopausal women treated with exemestane for the primary prevention of breast cancer: a nested substudy of the MAP.3 randomised controlled trial
    Cheung, Angela M.
    Tile, Lianne
    Cardew, Savannah
    Pruthi, Sandhya
    Robbins, John
    Tomlinson, George
    Kapral, Moira K.
    Khosla, Sundeep
    Majumdar, Sharmila
    Erlandson, Marta
    Scher, Judy
    Hu, Hanxian
    Demaras, Alice
    Lickley, Lavina
    Bordeleau, Louise
    Elser, Christine
    Ingle, James
    Richardson, Harriet
    Goss, Paul E.
    LANCET ONCOLOGY, 2012, 13 (03): : 275 - 284
  • [3] CLINICAL COOPERATIVE TRIALS OF THE NATIONAL-CANCER-INSTITUTE-OF-CANADA CLINICAL-TRIALS-GROUP BREAST-CANCER-SITE-GROUP
    PRITCHARD, KI
    CANCER, 1994, 74 (03) : 1150 - 1155
  • [4] Influence of Two Years of Exemestane on Bone Mineral Density in Postmenopausal Women at Increased Risk of Developing Breast Cancer; a Companion Study to the NCIC CTG MAP.3 Trial.
    Goss, P. E.
    Richardson, H.
    Ingle, J. N.
    Chlebowski, R. T.
    Fabian, C. J.
    Garber, J. E.
    Sarto, G. E.
    Hiltz, A.
    Tu, D.
    Cheung, A. M.
    CANCER RESEARCH, 2011, 71
  • [5] Docetaxel in patients with metastatic breast cancer: A phase II study of the National Cancer Institute of Canada - Clinical Trials Group
    Trudeau, ME
    Eisenhauer, EA
    Higgins, BP
    Letendre, F
    Lofters, WS
    Norris, BD
    Vandenberg, TA
    Delorme, F
    Muldal, AM
    JOURNAL OF CLINICAL ONCOLOGY, 1996, 14 (02) : 422 - 428
  • [6] Exemestane for primary prevention of breast cancer in postmenopausal women: NCIC CTG MAP.3-A randomized, placebo-controlled clinical trial
    Goss, P. E.
    Ingle, J. N.
    Ales-Martinez, J.
    Cheung, A.
    Chlebowski, R. T.
    Wactawski-Wende, J.
    McTiernan, A.
    Robbins, J.
    Johnson, K.
    Martin, L.
    Winquist, E.
    Sarto, G.
    Garber, J. E.
    Fabian, C. J.
    Pujol, P.
    Maunsell, E.
    Farmer, P.
    Gelmon, K. A.
    Tu, D.
    Richardson, H.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (18)
  • [7] Exemestane for primary prevention of breast cancer in postmenopausal women: NCIC CTG MAP.3-A randomized, placebo-controlled clinical trial
    Goss, P. E.
    Ingle, J. N.
    Ales-Martinez, J.
    Cheung, A.
    Chlebowski, R. T.
    Wactawski-Wende, J.
    McTiernan, A.
    Robbins, J.
    Johnson, K.
    Martin, L.
    Winquist, E.
    Sarto, G.
    Garber, J. E.
    Fabian, C. J.
    Pujol, P.
    Maunsell, E.
    Farmer, P.
    Gelmon, K. A.
    Tu, D.
    Richardson, H.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [8] Anticoagulation and bleeding: A pooled analysis of lung cancer trials of the National Cancer Institute of Canada Clinical Trials Group
    Le Maitre, A.
    Ding, K.
    Shepherd, F. A.
    Leighl, N. B.
    Arnold, A.
    Seymour, L.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [9] Early closure of clinical trials: The experience of the National Cancer Institute of Canada Clinical Trials Group.
    Parulekar, W.
    Pater, J. L.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 314S - 314S
  • [10] Temozolomide in metastatic breast cancer (MBC): A phase II trial of the National Cancer Institute of Canada-Clinical Trials Group (NCIC-CTG)
    Trudeau, ME
    Crump, M
    Charpentier, D
    Yelle, L
    Bordeleau, L
    Matthews, S
    Eisenhauer, E
    ANNALS OF ONCOLOGY, 2006, 17 (06) : 952 - 956
12345